TickerFacts.

DocGo Inc. (DCGO): R&D Expense

Annual figures by period end, from SEC filings.

$13.56M
Year ended 2025-12-31
$14.12M
Trailing 12 months to 2026-06-30
+36.1%
3-year compound annual growth
+62.7%
5-year compound annual growth
2020-12-31: $1.19M2021-12-31: $3.32M2022-12-31: $5.38M2023-12-31: $10.86M2024-12-31: $11.59M2025-12-31: $13.56M$13.56M
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$13.56M+17.0%2026-03-16, From 2025-01-01
2024-12-31$11.59M+6.7%2026-03-16, From 2024-01-01
2023-12-31$10.86M+101.7%2026-03-16, From 2023-01-01
2022-12-31$5.38M+62.2%2025-02-27, From 2022-01-01
2021-12-31$3.32M+179.1%2024-02-28, From 2021-01-01
2020-12-31$1.19Mn/a2022-03-15, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Health Services), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
DocGo Inc. (DCGO)2025-12-31$13.56M+17.0%
Omada Health, Inc. (OMDA)2025-12-31$40.68M+13.3%
GeneDx Holdings Corp. (WGS)2025-12-31$72.03M+57.5%
EUDA Health Holdings Ltd (EUDA)2025-12-31$249n/a

Compare DCGO, OMDA, WGS, EUDA side by side · Screen every company in Services-Health Services ↗